Is 2374 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6
Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 2374 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 2374 (¥735) is trading below our estimate of fair value (¥3041.86)
Significantly Below Fair Value: 2374 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2374?
Key metric: As 2374 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
The above table shows the Price to Earnings ratio for 2374. This is calculated by dividing 2374's market cap by their current
earnings.
What is 2374's PE Ratio?
PE Ratio
10.4x
Earnings
JP¥1.74b
Market Cap
JP¥18.10b
2374 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Earnings vs Industry: 2374 is good value based on its Price-To-Earnings Ratio (10.4x) compared to the JP Healthcare industry average (14.2x).
Price to Earnings Ratio vs Fair Ratio
What is 2374's PE Ratio
compared to its
Fair PE Ratio?
This is the expected PE Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
2374 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio
10.4x
Fair PE Ratio
16x
Price-To-Earnings vs Fair Ratio: 2374 is good value based on its Price-To-Earnings Ratio (10.4x) compared to the estimated Fair Price-To-Earnings Ratio (16x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.